Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic <i>Escherichia coli</i>

Larcombe, Sarah; Hutton, Melanie L.; Lyras, Dena

doi:10.1080/21645515.2018.1528836

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our systematic review showed that HBC conferred a beneficial effect on acute rotavirus infection [ 33 ]. It is suggested that the vaccination of cows with uropathogenic Escherichia coli can stimulate a targeted immune response [ 57 ], which could be an interesting area for future studies. The specific type of HBC, with neutralizing titer activity against H. pylori , appears to have clinical utility in inhibiting the binding of H. pylori to lipid receptors [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review

Hajihashemi,

Haghighatdoost,

Kassaian

et al. 2024

Syst Rev

View full text Add to dashboard Cite

Background Evidence on the effects of bovine colostrum (BC) supplementation on gastrointestinal (GI) diseases is conflicting. Objectives This systematic review summarized the findings of clinical trials (CTs) on the effects of BC supplementation on GI diseases. Methods A systematic search was conducted in online databases, including PubMed, ISI Web of Science, and Scopus, until March 2021 and updated until December 2023. CTs investigated BC’s effect on any measurable symptomatic change in terms of GI health as the primary outcome variable or as one of the outcomes in any population eligible for this systematic review. Results Out of 6881 records, 22 CTs (uncontrolled = 4, cross-over = 1, and parallel = 17) with 1427 patients were enrolled in the systematic review. Diarrhea, the most frequently evaluated symptom (20 interventional arms), was decreased in frequency with BC supplementation in 15 of these arms. However, most studies reported no change in its duration. BC supplementation consistently reduced stool frequency across all seven studies. Abdominal pain relief was noted in four interventional arms but showed no improvement in five others. Assessment of other GI symptoms was limited, yielding inconclusive results. Conclusions There is limited evidence on the effects of BC on GI diseases, with mixed findings. More well-designed controlled clinical trials are required to explore its effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review

Hajihashemi,

Haghighatdoost,

Kassaian

et al. 2024

Syst Rev

View full text Add to dashboard Cite

show abstract

“…For determination of minimum inhibitory concentrations (MIC), extracts (250 to 0.5 µg mL −1 ) or synthesized compounds (100 to 0.0002 µM) were serially diluted in microtiter plates. Bacterial suspension (90 µL, OD 600 nm 0.001) was added to each well and plates were incubated at 37 • C for either 18 h (MRSA, P. aeruginosa PAO1, E. coli EC958) or 7 days (M. tuberculosis H37Rv) as described previously (Harrison et al, 2017;Irene et al, 2019;Larcombe et al, 2019;Mouton et al, 2019). Resazurin (10 µL; 0.05% w/v) was added and plates were incubated for 3 h or 24 h (M. tuberculosis) at 37 • C. The inhibitory activity was calculated by visual determination of color change within wells or detection of fluorescence at 590 nm using a FLUOstar Omega microplate reader (BMG Labtech, Germany).…”

Section: Bacterial Inhibition Assaysmentioning

confidence: 99%

Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis

2020

View full text Add to dashboard Cite

Drug resistant bacteria have emerged, so robust methods are needed to evaluate combined activities of known antibiotics as well as new synthetic compounds as novel antimicrobial agents to treatment efficacy in severe bacterial infections. Marine natural products (MNPs) have become new strong leads in the drug discovery endeavor and an effective alternative to control infections. Herein, we report the bioassay guided fractionation of marine extracts from the sponges Lendenfeldia, Ircinia, and Dysidea that led us to identify novel compounds with antimicrobial properties. Chemical synthesis of predicted compounds and their analogs has confirmed that the proposed structures may encode novel chemical structures with promising antimicrobial activity against the medically important pathogens. Several of the synthetic analogs exhibited potent and broad spectrum in vitro antibacterial activity, especially against the Methicillin-resistant Staphylococcus aureus (MRSA) (MICs to 12.5 μM), Mycobacterium tuberculosis (MICs to 0.02 μM), uropathogenic Escherichia coli (MIC o 6.2 μM), and Pseudomonas aeruginosa (MIC to 3.1 μM). Checkerboard assay (CA) and time-kill studies (TKS) experiments analyzed with the a pharmacodynamic model, have potentials for in vitro evaluation of new and existing antimicrobials. In this study, CA and TKS were used to identify the potential benefits of an antibiotic combination (i.e., synthetic compounds, vancomycin, and rifampicin) for the treatment of MRSA and M. tuberculosis infections. CA experiments indicated that the association of compounds 1a and 2a with vancomycin and compound 3 with rifampicin combination have a synergistic effect against a MRSA and M. tuberculosis infections, respectively. Furthermore, the analysis of TKS uncovered bactericidal and time-dependent properties of the synthetic compounds that may be due to variations in hydrophobicity and mechanisms of action of the molecules tested. The results of cross-referencing antimicrobial activity, and toxicity, CA, and Time-Kill experiments establish that these synthetic compounds are promising potential leads, with a favorable therapeutic index for antimicrobial drug development.

show abstract

“…Immunological approaches may represent further options to eradicate intestinal carriage of MDRO, e.g. the application of hyperimmune bovine colostrum directed against globally disseminated multidrug-resistant Escherchia coli lineage ST131, which has been successfully tested in a mouse model, but is in the very early stages of development [19].…”

mentioning

confidence: 99%

Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract

Kuijper

Vendrik

Vehreschild

2019

Clinical Microbiology and Infection

View full text Add to dashboard Cite

In this issue, CMI features the first randomized controlled trial assessing a decolonization regimen of oral antibiotics followed by a faecal microbiota transfer (FMT) for the eradication of multidrugresistant Enterobacteriaceae from the human intestinal tract [1]. The authors are to be congratulated for taking up the challenge of conducting this trial in a highly complex and rapidly changing regulatory environment. There was no statistically significant advantage for the intervention group, but the study of Huttner et al. should be placed in a historical context, as the study was well designed and only suffered from inclusion of insufficient patients.Based on the results of this published study, one might wonder whether there truly is potential for the eradication of Gram-negative multidrug-resistant organisms (MDRO), including extended-spectrum b-lactamase, carbapenemase-producing Enterobacteriaceae, and non-fermenters (Pseudomonas and Acinetobacter spp.), as well as associated antibiotic-resistance genes (ARG) through the manipulation of the gut microbiota. It remains largely unknown which conditions predispose to their acquisition and specifically how the microbiota may facilitate or prevent this event. Transition from colonization to infection with MDRO may be of clinical relevance for non-immunocompromised patients, such as individuals who are at risk for development of ventilator-associated pneumonia, cathether-associated urinary tract infections or bloodstream infections. However, it is of more importance in significantly immunocompromised patients, such as solid organ transplant and stem cell recipients, as well as patients receiving intensive chemotherapy. These individuals are considered an important target population for eradication strategies. Unfortunately, severely immunocompromised patients and solid organ transplant patients were excluded in the study of Huttner et al. [1].There are many uncertainties on the efficacy of eradication therapies for Gram-negative MDRO. So far, all eradication strategies based on the use of orally non-absorbable antibiotics have failed, and a recently completed ESCMID guideline does not recommend this approach [2]. Nevertheless, we believe that manipulation of the gut microbiota could rely on a broad range of other interventions. The administration of prebiotics or probiotics, FMTs, synthetic microbial communities or bacteriolytic phages has not been sufficiently assessed for its potential efficacy.The presence of MDRO in the intestinal tract of patients with recurrent Clostridium difficile infections (CDI) and the success of FMT, prompted observations on the application of FMT to eradicate MDRO in individuals with CDI. On average, people with CDI harbour greater numbers and a more diverse set of ARG than healthy controls. ARG sub-studies of individuals receiving FMT for the treatment of recurrent CDI have shown significant reductions in the quantity of ARG after FMT [3e5]. However, none of these studies included control groups, and the patients with recurrent CDI hav...

show abstract

Hyperimmune bovine colostrum reduces gastrointestinal carriage of uropathogenic Escherichia coli

Cited by 6 publications

References 29 publications

Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review

Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review

Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis

Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract

Contact Info

Product

Resources

About